{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000011","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.626111+00:00","generated_at":"2026-05-16T06:53:47.300386+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Halozyme raises 2026 guidance; acquires Surf Bio for $300M upfront","bullets":["Preliminary 2025 revenue estimated at $1,385-1,400M (+36-38% YoY); royalties $865-870M (+51-52% YoY).","2026 revenue guidance raised to $1,710-1,810M (+23-30% YoY) from prior $1,430-1,530M; royalty revenue now >$1B.","2026 non-GAAP diluted EPS guidance raised to $7.75-8.25 (prior $6.50-7.00); Adjusted EBITDA $1,125-1,205M.","Acquired Surf Bio for $300M upfront plus up to $100M milestones; adds hyperconcentration technology for biologics.","Surf Bio technology enables 500 mg/mL antibody concentrations for single auto-injector subcutaneous delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000011","json":"https://secwatch.observer/filing/0001159036-26-000011.json","markdown":"https://secwatch.observer/filing/0001159036-26-000011.md","text":"https://secwatch.observer/filing/0001159036-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000011/0001159036-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000011/halo-20260128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T06:53:47.300386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}